UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 25,
2011
|
VENTRUS
BIOSCIENCES, INC.
|
||
|
(Exact
name of registrant as specified in its charter)
|
|
Delaware
|
20-8729264
|
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer ID Number)
|
|
787
7th
Avenue, 48th
Floor, New York, New York
|
10019
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code
|
(212)
554-4300
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01. Other Events.
On
January 25, 2011, the Board of Directors of Ventrus Biosciences, Inc.
established the Business Development Committee and appointed directors Russell
H. Ellison, Myron Z. Holubiak and Thomas Rowland to the Committee, with Mr.
Rowland appointed as Chair of the Committee. As Chair, Mr. Rowland
will be responsible for pursuing business development for Ventrus.
Also on
January 25, 2011, the Board of Directors of Ventrus elected Russell H. Ellison
as Chairman of the Board, following Mr. Rowland’s resignation immediately prior
to the appointment. The appointment of Dr. Ellison as Chairman of the
Board is a term of his employment agreement. The terms of Dr.
Ellison’s employment agreement became effective upon the completion of Ventrus’
initial public offering on December 22, 2010.
2
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
|
VENTRUS
BIOSCIENCES, INC.
|
|
|
Date: January
27, 2011
|
/s/ David J.
Barrett
|
|
David
J. Barrett, Chief Financial
Officer
|
3